Targeting a specific protein in breast cancer to improve treatment outcomes
Development of chemical probe targeting NSD3 SET domain in breast cancer
This study is looking at new ways to create medicines that can block a protein called NSD3, which is linked to breast cancer growth, to help develop better treatment options for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11030849 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule chemical probes that specifically target the NSD3 SET domain, a protein implicated in breast cancer progression. By understanding how this protein contributes to tumor growth, the researchers aim to create effective inhibitors that can block its activity. The approach involves testing these compounds in breast cancer models, particularly those with NSD3 amplifications, to evaluate their impact on cancer cell growth and survival. Patients may benefit from new treatment options that arise from this innovative strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are breast cancer patients whose tumors exhibit amplifications of the NSD3 gene.
Not a fit: Patients without breast cancer or those whose tumors do not have NSD3 amplifications may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for breast cancer patients with NSD3 amplifications.
How similar studies have performed: While targeting similar proteins in cancer has shown promise, this specific approach to inhibit NSD3 is novel and has not been extensively tested in prior studies.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Cierpicki, Tomasz — University of Michigan at Ann Arbor
- Study coordinator: Cierpicki, Tomasz
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.